CombiGene: €3.3m

Case

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. CombiGene was granted €3.3 million from the SME Instrument HORIZON 2020, phase 2.

“GAEU has in a significant way contributed to the successful outcome of our Horizon 2020-application. Both their experience of the complex application procedure and the professional hands-on support that we got throughout the entire process were very valuable. I look forward to a continued cooperation with them in the future.”

- Jan Nilsson, CEO, CombiGene